Table 8.
Biochemical parameters of the study subjects by body size phenotype
| Metabolically healthy* | Metabolically unhealthy† | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall (n 521) | Normal weight n 145 (27⋅8 %) | Overweight n 149 (28⋅6 %) | Obese n 56 (10⋅7 %) | Normal weight n 11 (2⋅1 %) | Overweight n 42 (8⋅1 %) | Obese n 118 (22⋅6 %) | ||||||||
| Median | IQR | Median | IQR | Median | IQR | Median | IQR | Median | IQR | Median | IQR | Median | IQR | |
| Biochemical parameters | ||||||||||||||
| TChol (mmol/l) | 4⋅9 | 1⋅1 | 4⋅6 | 1⋅1 | 4⋅8 | 1⋅0 | 4⋅9 | 0⋅9 | 5⋅6 | 1⋅0 | 5⋅2 | 1⋅5 | 4⋅9 | 1⋅2 |
| LDL-C (mmol/l) | 2⋅9 | 1⋅1 | 2⋅6 | 1⋅0 | 2⋅8 | 0⋅9 | 2⋅9 | 0⋅9 | 3⋅7 | 0⋅7 | 3⋅1 | 1⋅2 | 3⋅1 | 1⋅2 |
| HDL-C (mmol/l) | 1⋅4 | 0⋅5 | 1⋅7 | 0⋅5 | 1⋅5 | 0⋅4 | 1⋅6 | 0⋅4 | 1⋅2 | 0⋅1 | 1⋅2 | 0⋅4 | 1⋅2 | 0⋅3 |
| Triglycerides (mmol/l) | 1⋅0 | 0⋅7 | 0⋅8 | 0⋅3 | 0⋅9 | 0⋅6 | 0⋅9 | 0⋅4 | 1⋅6 | 0⋅9 | 1⋅6 | 1⋅3 | 1⋅5 | 0⋅8 |
| Uric Acid (umol/l) | 280⋅0 | 95⋅0 | 241⋅0 | 85⋅0 | 280⋅0 | 90⋅0 | 286⋅0 | 94⋅0 | 273⋅0 | 138⋅0 | 308⋅5 | 120⋅0 | 311⋅5 | 113⋅0 |
| FPG (mmol/l) | 5⋅1 | 0⋅7 | 4⋅9 | 0⋅5 | 5⋅1 | 0⋅5 | 5⋅0 | 0⋅4 | 5⋅6 | 1⋅4 | 5⋅6 | 0⋅8 | 5⋅6 | 0⋅9 |
| HBA1c (%) | 5⋅3 | 0⋅4 | 5⋅2 | 0⋅3 | 5⋅2 | 0⋅4 | 5⋅3 | 0⋅3 | 5⋅3 | 0⋅2 | 5⋅4 | 0⋅5 | 5⋅6 | 0⋅7 |
| HOMA-IR | 1⋅7 | 1⋅2 | 1⋅1 | 0⋅9 | 1⋅6 | 0⋅9 | 1⋅5 | 0⋅9 | 1⋅1 | 0⋅9 | 2⋅2 | 1⋅6 | 2⋅4 | 1⋅1 |
| Vitamin D (ng/l) | 18⋅0 | 8⋅0 | 19⋅0 | 10⋅0 | 18⋅0 | 10⋅0 | 18⋅0 | 7⋅5 | 15⋅0 | 4⋅0 | 17⋅0 | 6⋅0 | 18⋅0 | 7⋅0 |
| ALP (U/l) | 63⋅0 | 21⋅0 | 55⋅0 | 20⋅0 | 63⋅0 | 22⋅0 | 63⋅5 | 15⋅5 | 63⋅0 | 13⋅0 | 67⋅5 | 15⋅0 | 70⋅0 | 18⋅0 |
| GGT (U/l) | 19⋅0 | 16⋅0 | 14⋅0 | 9⋅0 | 18⋅0 | 16⋅0 | 18⋅0 | 14⋅5 | 17⋅0 | 46⋅0 | 29⋅0 | 26⋅0 | 25⋅0 | 18⋅0 |
| ALT (U/l) | 17⋅0 | 13⋅0 | 14⋅0 | 9⋅0 | 17⋅0 | 13⋅0 | 16⋅0 | 14⋅5 | 18⋅0 | 30⋅0 | 23⋅0 | 23⋅0 | 22⋅0 | 16⋅0 |
| Ferritin (ng/ml) | 53⋅0 | 105⋅0 | 28⋅0 | 55⋅0 | 52⋅0 | 112⋅0 | 52⋅0 | 84⋅5 | 85⋅0 | 120⋅0 | 77⋅5 | 175⋅0 | 85⋅0 | 147⋅0 |
| TSH (micIU/ml) | 1⋅5 | 1⋅0 | 1⋅5 | 1⋅2 | 1⋅4 | 0⋅8 | 1⋅7 | 1⋅2 | 1⋅3 | 1⋅3 | 1⋅5 | 0⋅9 | 1⋅5 | 1⋅1 |
| FT4 (pmol/l) | 14⋅6 | 2⋅5 | 14⋅7 | 2⋅3 | 15⋅1 | 2⋅6 | 14⋅4 | 2⋅1 | 14⋅8 | 2⋅9 | 14⋅7 | 2⋅2 | 14⋅4 | 2⋅8 |
| LAP | 27⋅5 | 36⋅5 | 11⋅6 | 9⋅0 | 23⋅7 | 18⋅4 | 33⋅4 | 22⋅1 | 34⋅4 | 30⋅7 | 52⋅0 | 35⋅6 | 65⋅9 | 45⋅9 |
| log(TG/HDL-C) | −0⋅2 | 0⋅4 | −0⋅4 | 0⋅2 | −0⋅2 | 0⋅3 | −0⋅3 | 0⋅3 | 0⋅1 | 0⋅3 | 0⋅1 | 0⋅4 | 0⋅1 | 0⋅3 |
| PLR | 134⋅4 | 62⋅3 | 142⋅9 | 54⋅8 | 135⋅2 | 56⋅7 | 127⋅6 | 54⋅1 | 121⋅7 | 78⋅7 | 127⋅8 | 70⋅5 | 119⋅8 | 65⋅3 |
| NLR | 2⋅0 | 0⋅9 | 2⋅1 | 1⋅0 | 1⋅9 | 0⋅8 | 2⋅0 | 1⋅0 | 1⋅9 | 1⋅0 | 1⋅9 | 0⋅6 | 2⋅1 | 1⋅0 |
Data are expressed as median + IQR.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; BMI, body mass index; DBP, diastolic blood pressure; F, female; FPG, fasting plasma glucose; FT4, free thyroxine; GGT, Gamma glutamyl transferase; HBA1c, haemoglobin A1c; HDL-C, high density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance; LAP, lipid accumulation product; LDL-C, low density lipoprotein cholesterol; M, male; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio; PMH, past medical history; SBP, systolic blood pressure; TG, triglycerides; TSH, thyroxine stimulating hormone; WC, waist circumference.
Metabolically healthy – individuals having ≤1 NCEP-ATPIII criteria (consisting of waist circumference >102 cm in men and >88 cm in women; systolic or diastolic blood pressure ≥130/85 mmHg or on antihypertensive medication; serum triglycerides ≥1⋅69 mmol/l or on lipid-lowering medication; HDL-C <1⋅03 mmol/l in men and <1⋅29 mmol/l in women or on treatment aimed to increase HDL-C; fasting glucose ≥5⋅6 mmol/l or on antihyperglycemic agents.
Metabolically unhealthy – individuals having ≥2 metabolic abnormalities of the NCEP-ATPIII criteria.